Pancreatic Cancer Research

ResearcherSichuan UniversityActive in the last 2 years

Bole Tian

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0000-2951-0643; OpenAlex author ID A5101541179. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
26
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: 2 papers · 2024: none · 2025: 2 papers

Papers 9

  1. Synchronous surgery combined preoperative chemotherapy benefits patients suffering pancreatic ductal adenocarcinoma with liver metastases: a systematic review … Last author DOI 10.1038/s41598-025-13811-9↗
  2. The role of pulmonary metastasectomy in patients suffering pancreatic ductal adenocarcinoma with lung metastases: a systematic review and meta-analysis. Last author DOI 10.3389/fsurg.2025.1535212↗
  3. Perioperative and long-term survival outcomes of pancreatectomy with arterial resection in borderline resectable or locally advanced pancreatic cancer followin… Last author DOI 10.1097/js9.0000000000000742↗
  4. Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastatic pancreatic ductal adenocarcinoma: an o… Last author DOI 10.21203/rs.3.rs-3677396/v1↗
  5. Letter to the editor: the nonnegligible effect of neoadjuvant therapy for patients with borderline resectable pancreatic ductal adenocarcinoma. Last author DOI 10.21037/gs-21-379↗
  6. MicroRNA-204-3p inhibits metastasis of pancreatic cancer via downregulating MGAT1. Last author PMID 34761629↗
  7. Alteration of Transforming Growth Factor β Signaling Pathway Predicts Worse Prognosis in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000001522↗
  8. Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer. Last author DOI 10.2147/dddt.s261017↗
  9. Acute pancreatitis in patients with pancreatic cancer: Timing of surgery and survival duration. First author DOI 10.1097/md.0000000000005908↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kang Xue · 3 shared papers, 2023–2025 · strength 0.90
  2. Pengcheng Zhao · 2 shared papers, 2023–2025 · strength 0.57
  3. Pengcheng Zhao · 1 shared paper, 2025 · strength 0.33
  4. Zihe Wang · 1 shared paper, 2025 · strength 0.33
  5. Li Wang · 1 shared paper, 2021 · strength 0.19
  6. Xin Zhang · 1 shared paper, 2021 · strength 0.19
  7. Xiao Tan · 1 shared paper, 2021 · strength 0.17
  8. Wei Liu · 1 shared paper, 2021 · strength 0.17
  9. Shaojun Li · 1 shared paper, 2017 · strength 0.15
  10. Chengjian Zhao · 1 shared paper, 2023 · strength 0.14
  11. Wanrui Lv · 1 shared paper, 2023 · strength 0.14
  12. Zixing Huang · 1 shared paper, 2023 · strength 0.14
  13. Junjie Xiong · 1 shared paper, 2023 · strength 0.14
  14. Ke Cheng · 1 shared paper, 2023 · strength 0.14
  15. Dan Cao · 1 shared paper, 2023 · strength 0.14
  16. Rui Wang · 1 shared paper, 2023 · strength 0.14
  17. Chen Yang · 1 shared paper, 2020 · strength 0.11
  18. Yi Zhang · 1 shared paper, 2020 · strength 0.11
  19. Xing Huang · 1 shared paper, 2020 · strength 0.11
  20. Chao Wu · 1 shared paper, 2020 · strength 0.11
  21. Li Wang · 1 shared paper, 2020 · strength 0.11
  22. Xubao Liu · 1 shared paper, 2020 · strength 0.11
  23. Yu Mou · 1 shared paper, 2020 · strength 0.11
  24. Li Mao · 1 shared paper, 2020 · strength 0.11
  25. Dan Cao · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.